Brokers Issue Forecasts for Haemonetics FY2027 Earnings

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research decreased their FY2027 earnings per share estimates for shares of Haemonetics in a report released on Monday, February 3rd. Zacks Research analyst R. Department now expects that the medical instruments supplier will earn $5.90 per share for the year, down from their previous forecast of $5.91. The consensus estimate for Haemonetics’ current full-year earnings is $4.59 per share.

Several other equities research analysts have also commented on the company. Barrington Research reiterated an “outperform” rating and set a $108.00 price objective on shares of Haemonetics in a research note on Wednesday, December 4th. Needham & Company LLC restated a “buy” rating and issued a $112.00 price objective on shares of Haemonetics in a report on Tuesday, December 3rd. JPMorgan Chase & Co. began coverage on shares of Haemonetics in a report on Friday, December 6th. They set an “overweight” rating and a $116.00 target price for the company. Finally, Raymond James upgraded shares of Haemonetics from an “outperform” rating to a “strong-buy” rating and set a $120.00 price target on the stock in a research report on Friday, November 8th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $108.78.

Haemonetics Stock Up 3.4 %

HAE stock opened at $71.26 on Wednesday. The stock has a market capitalization of $3.58 billion, a P/E ratio of 29.57, a P/E/G ratio of 1.07 and a beta of 0.39. Haemonetics has a 52 week low of $65.73 and a 52 week high of $97.97. The firm has a 50-day simple moving average of $77.77 and a 200-day simple moving average of $78.79. The company has a quick ratio of 2.09, a current ratio of 3.49 and a debt-to-equity ratio of 1.39.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $1.12 EPS for the quarter, topping the consensus estimate of $1.09 by $0.03. Haemonetics had a net margin of 9.10% and a return on equity of 22.67%. The company had revenue of $345.50 million during the quarter, compared to analyst estimates of $342.57 million. During the same quarter in the previous year, the firm earned $0.99 EPS. The firm’s revenue was up 8.6% compared to the same quarter last year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HAE. Creative Planning purchased a new stake in Haemonetics in the second quarter valued at $368,000. Handelsbanken Fonder AB raised its holdings in Haemonetics by 23.9% in the 3rd quarter. Handelsbanken Fonder AB now owns 17,095 shares of the medical instruments supplier’s stock valued at $1,374,000 after buying an additional 3,300 shares during the period. Dynamic Advisor Solutions LLC lifted its position in Haemonetics by 10.1% in the third quarter. Dynamic Advisor Solutions LLC now owns 20,154 shares of the medical instruments supplier’s stock valued at $1,620,000 after buying an additional 1,848 shares during the last quarter. West Coast Financial LLC boosted its stake in Haemonetics by 2.2% during the third quarter. West Coast Financial LLC now owns 47,182 shares of the medical instruments supplier’s stock worth $3,792,000 after buying an additional 1,013 shares during the period. Finally, Inspire Investing LLC boosted its stake in Haemonetics by 19.7% during the third quarter. Inspire Investing LLC now owns 5,130 shares of the medical instruments supplier’s stock worth $412,000 after buying an additional 845 shares during the period. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.